JP7478975B2 - チカグレロル活性を逆転させる方法 - Google Patents

チカグレロル活性を逆転させる方法 Download PDF

Info

Publication number
JP7478975B2
JP7478975B2 JP2021515473A JP2021515473A JP7478975B2 JP 7478975 B2 JP7478975 B2 JP 7478975B2 JP 2021515473 A JP2021515473 A JP 2021515473A JP 2021515473 A JP2021515473 A JP 2021515473A JP 7478975 B2 JP7478975 B2 JP 7478975B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
seq
ticagrelor
hours
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021515473A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022501368A5 (enExample
JP2022501368A (ja
Inventor
リー，ジョン
ジェームス バランス，デイヴィット
Original Assignee
エスエフジェイ ファーマ エックス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69887913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7478975(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エスエフジェイ ファーマ エックス，インコーポレイテッド filed Critical エスエフジェイ ファーマ エックス，インコーポレイテッド
Publication of JP2022501368A publication Critical patent/JP2022501368A/ja
Publication of JP2022501368A5 publication Critical patent/JP2022501368A5/ja
Priority to JP2024062468A priority Critical patent/JP2024096134A/ja
Application granted granted Critical
Publication of JP7478975B2 publication Critical patent/JP7478975B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021515473A 2018-09-20 2019-09-20 チカグレロル活性を逆転させる方法 Active JP7478975B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024062468A JP2024096134A (ja) 2018-09-20 2024-04-09 チカグレロル活性を逆転させる方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862733892P 2018-09-20 2018-09-20
US62/733,892 2018-09-20
US201962806225P 2019-02-15 2019-02-15
US62/806,225 2019-02-15
US201962836373P 2019-04-19 2019-04-19
US62/836,373 2019-04-19
PCT/US2019/052173 WO2020061465A1 (en) 2018-09-20 2019-09-20 Methods of reversing ticagrelor activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024062468A Division JP2024096134A (ja) 2018-09-20 2024-04-09 チカグレロル活性を逆転させる方法

Publications (3)

Publication Number Publication Date
JP2022501368A JP2022501368A (ja) 2022-01-06
JP2022501368A5 JP2022501368A5 (enExample) 2022-09-27
JP7478975B2 true JP7478975B2 (ja) 2024-05-08

Family

ID=69887913

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021515473A Active JP7478975B2 (ja) 2018-09-20 2019-09-20 チカグレロル活性を逆転させる方法
JP2024062468A Pending JP2024096134A (ja) 2018-09-20 2024-04-09 チカグレロル活性を逆転させる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024062468A Pending JP2024096134A (ja) 2018-09-20 2024-04-09 チカグレロル活性を逆転させる方法

Country Status (13)

Country Link
US (2) US12617870B2 (enExample)
EP (2) EP3852617B1 (enExample)
JP (2) JP7478975B2 (enExample)
KR (2) KR20250161038A (enExample)
CN (1) CN113194821B (enExample)
AU (1) AU2019342755B2 (enExample)
CA (1) CA3113654A1 (enExample)
DK (1) DK3852617T3 (enExample)
ES (1) ES3042247T3 (enExample)
FI (1) FI3852617T3 (enExample)
MX (1) MX2021003298A (enExample)
PL (1) PL3852617T3 (enExample)
WO (1) WO2020061465A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024096134A (ja) * 2018-09-20 2024-07-12 エスエフジェイ ファーマ エックス，インコーポレイテッド チカグレロル活性を逆転させる方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2021125449A (ru) 2014-10-01 2021-09-16 Медиммьюн Лимитед Антитела к тикагрелору и способы применения
WO2022240754A2 (en) * 2021-05-10 2022-11-17 Phasebio Pharmaceuticals, Inc. Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody
KR102952285B1 (ko) 2021-07-13 2026-04-13 주식회사 엘지에너지솔루션 전지의 용접 상태 검사 방법
WO2026019858A1 (en) * 2024-07-16 2026-01-22 SFJ Pharma X, Inc. Methods of reversing ticagrelor activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017535252A (ja) 2014-10-01 2017-11-30 メディミューン リミテッド チカグレロルに対する抗体および使用方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
JPH03154867A (ja) * 1989-11-13 1991-07-02 Teijin Ltd １―メチルアデノシンの免疫学的測定方法，そのための測定試薬及び試薬キット
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AR017014A1 (es) 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
JP2006512102A (ja) 2002-04-11 2006-04-13 メディミューン・ヴァクシンズ・インコーポレーテッド 噴霧乾燥による生物活性材料の防腐
WO2003087339A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
EP1494651A4 (en) 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
KR20050088175A (ko) 2002-12-17 2005-09-02 메드이뮨 백신즈 인코포레이티드 생물활성 물질의 고압 분무 건조
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
MX2008009220A (es) 2006-01-17 2008-10-10 Biolex Therapeutics Inc Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas.
TWI391378B (zh) 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
NZ574804A (en) 2006-08-11 2012-02-24 Schering Corp Antibodies to il-17a
CL2007002668A1 (es) 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
JP2014516982A (ja) * 2011-06-01 2014-07-17 アストラゼネカ アクチボラグ 新規なチカグレロル共結晶
EP2729488A4 (en) 2011-07-06 2015-01-14 Medimmune Llc PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES
IN2014CN02806A (enExample) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US10000565B2 (en) * 2012-11-16 2018-06-19 Novartis Ag Use of IL-1 β binding antibodies for treating peripheral arterial disease
HK1219044A1 (zh) * 2013-03-15 2017-03-24 艾伯维德国有限责任两合公司 抗egfr抗体药物偶联物制剂
US10259842B2 (en) * 2013-05-15 2019-04-16 Medimmune, Llc Purification of recombinantly produced polypeptides
US20150313595A1 (en) 2014-05-02 2015-11-05 W. L. Gore & Associates, Inc. Anastomosis Devices
WO2016033424A1 (en) * 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
JP2018502894A (ja) * 2015-01-27 2018-02-01 アストラゼネカ アクチボラグ 心筋梗塞の病歴がある患者においてアテローム血栓性イベントを治療または予防する方法
KR101916956B1 (ko) * 2016-12-13 2018-11-08 보령제약 주식회사 티카그렐러의 신규한 고체 형태 및 이의 제조방법
CN118320078A (zh) * 2016-12-23 2024-07-12 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
JP2020509025A (ja) * 2017-03-01 2020-03-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ モノクローナル抗体製剤
EP3852617B1 (en) 2018-09-20 2025-09-10 SFJ Pharma X, Inc. Use of antibody fragments for reversing ticagrelor activity
WO2022240754A2 (en) 2021-05-10 2022-11-17 Phasebio Pharmaceuticals, Inc. Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017535252A (ja) 2014-10-01 2017-11-30 メディミューン リミテッド チカグレロルに対する抗体および使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BUCHANAN A; NEWTON P; PEHRSSON S; ET AL，STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF A SPECIFIC ANTIDOTE FOR TICAGRELOR，BLOOD，米国，AMERICAN SOCIETY OF HEMATOLOGY，2015年05月28日，VOL:125, NR:22，PAGE(S):3484 - 3490，http://dx.doi.org/10.1182/blood-2015-01-622928
Thomas MEYER and Helmuth HILZ，Eur. J. Biochem.，1986年，Vol.155，p.157-165

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024096134A (ja) * 2018-09-20 2024-07-12 エスエフジェイ ファーマ エックス，インコーポレイテッド チカグレロル活性を逆転させる方法
US12617870B2 (en) 2018-09-20 2026-05-05 SFJ Pharmaceutical X, LTD. Methods of reversing ticagrelor activity

Also Published As

Publication number Publication date
WO2020061465A1 (en) 2020-03-26
EP4653465A2 (en) 2025-11-26
US20260209389A1 (en) 2026-07-23
EP4653465A3 (en) 2026-01-07
EP3852617A1 (en) 2021-07-28
DK3852617T3 (da) 2025-10-20
US20210347915A1 (en) 2021-11-11
EP3852617B1 (en) 2025-09-10
ES3042247T3 (en) 2025-11-19
FI3852617T3 (fi) 2025-10-21
KR20250161038A (ko) 2025-11-14
AU2019342755B2 (en) 2025-12-11
CN113194821A (zh) 2021-07-30
JP2022501368A (ja) 2022-01-06
PL3852617T3 (pl) 2026-01-26
EP3852617A4 (en) 2022-08-24
JP2024096134A (ja) 2024-07-12
AU2019342755A1 (en) 2021-05-06
KR102880762B1 (ko) 2025-11-03
CN113194821B (zh) 2025-07-04
CA3113654A1 (en) 2020-03-26
KR20210091698A (ko) 2021-07-22
MX2021003298A (es) 2021-08-11
US12617870B2 (en) 2026-05-05

Similar Documents

Publication Publication Date Title
JP2024096134A (ja) チカグレロル活性を逆転させる方法
US11147879B2 (en) Methods of treating or preventing stent thrombosis
JP2014077005A (ja) 抗血小板療法中の血小板抑制のメンテナンス
JP2026048712A (ja) 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン
US20230192895A1 (en) Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody
JP2022501368A5 (enExample)
JP2023507795A5 (enExample)
AU2017355613B2 (en) Treatment regimens
Pickett et al. Prolonged Infusion of Eptifibatide as Bridge Therapy Between Bare‐Metal Stent Insertion and Cardiovascular Surgery: Case Report and Review of the Literature
JP2023541249A (ja) 治療用抗体製剤
US20200055942A1 (en) Treatment regimens
US20250032578A1 (en) Use of a pharmaceutical composition
WO2019025847A1 (en) TREATMENT DIAGRAMS
Musgrave DOAC Reversal Agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220915

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230821

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240306

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240409

R150 Certificate of patent or registration of utility model

Ref document number: 7478975

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157